The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development
From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations
SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing...
SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing...
San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care...
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.
First Batch of 300,000 Units to be Fully Delivered in October
Ainos, Inc. (NASDAQ: AIMD) is engaged as a diversified medical technology company, which is focused on developing innovative point-of-care testing
/PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care...